Transplantation Proceedings
Volume 36, Issue 1 , Pages 29-34 , January 2004

Advances in pre- and posttransplant immunologic testing in kidney transplantation

  • C Süsal

      Affiliations

    • Department of Transplantation Immunology, Institute of Immunology University of Heidelberg, Heidelberg, Germany
    • Corresponding Author InformationAddress reprint requests to Dr C. Süsal, Institute of Immunology, University of Heidelberg, INF 305, D-69120 Heidelberg, Germany.
    • ,
  • S Pelzl

      Affiliations

    • Department of Transplantation Immunology, Institute of Immunology University of Heidelberg, Heidelberg, Germany
    • ,
  • T Simon

      Affiliations

    • Department of Transplantation Immunology, Institute of Immunology University of Heidelberg, Heidelberg, Germany
    • ,
  • G Opelz

      Affiliations

    • Department of Transplantation Immunology, Institute of Immunology University of Heidelberg, Heidelberg, Germany

References 

  1. Patel R, Terasaki PI. Significance of the crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735
  2. Shenton BK. The detection and relevance of pretransplant antibodies. Transplant Immunol. 1994;2:135
  3. Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antibodies (an alternative to panel studies by lymphocytotoxicity). Transplantation. 1993;55:192
  4. Müller-Steinhardt M, Fricke L, Kirchner H, et al.  Monitoring of anti-HLA class I and II-antibodies by flow cytometry in patients after first cadaveric kidney transplantation. Clin Transplant. 2000;14:85
  5. Lobashevsky AL, Senkbeil RW, Shoaf J, et al.  Specificity of preformed alloantibodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant. 2000;14:533
  6. Christiaans MH, Nieman F, van Hooff JP, et al.  Detection of HLA class I and II antibodies by ELISA and complement-dependent cytotoxicity before and after transplantation. Transplantation. 2000;69:917
  7. Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation. 2002;73:1269
  8. Cerilli GJ, Brasile L, Galouzis T, et al.  Clinical significance of antimonocyte antibody in kidney transplant recipients. Transplantation. 1981;32:495
  9. Süsal C, Pelzl S, Opelz G: Relationship between kidney graft rejection and pretransplant anti-HLA antibody status and serum CD30 content. In: Proceedings of the 13th IHWC, Seattle, Washington (in press)
  10. Pelzl S, Opelz G, Wiesel M, et al.  Soluble CD30 as a predictor of kidney graft outcome. Transplantation. 2002;73:3
  11. Süsal C, Pelzl S, Döhler B, et al.  Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol. 2002;13:1650
  12. Del Prete G, De Carli M, Almerigogna F, et al.  Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995;9:81
  13. Romagnani S, Del Prete G, Maggi E, et al.  CD30 and type 2 T helper (Th2) responses. J Leukoc Biol. 1995;57:726
  14. Frezzolini A, Paradisi M, Ruffelli M, et al.  Soluble CD30 in pediatric patients with atopic dermatitis. Allergy. 1997;52:106
  15. McMillan SA, McDonnell GV, Douglas JP, et al.  Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis. Neurology. 1998;51:1156
  16. Strom TB, Roy-Chaudhury P, Manfro R, et al.  The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol. 1996;8:688
  17. Weimer R, Zipperle S, Daniel V, et al.  Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection. Transplantation. 1996;62:1606
  18. Martinez OM, Villanueva J, Abtahi S, et al.  CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation. 1998;65:1240
  19. Chan KW, Hopke CD, Krams SM, et al.  CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses. J Immunol. 2002;169:1784
  20. Mytilineos J, Opelz G, Wujciak T, et al.  HLA compatibility and organ transplant survival. Rev Immunogenet. 1999;1:334
  21. Süsal C, Pelzl S, Opelz G: Strong HLA matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 76:1231, 2003
  22. Süsal C, Pelzl S, Opelz G. High pretransplant serum sCD30 content as a possible explanation for the high rejection rate in young kidney graft recipients. Pediatr Transplant. 2003;7:48
  23. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. Transplant Proc. 1997;29:73
  24. Matas AJ. Acute rejection is a major risk factor for chronic rejection. Transplant Proc. 1998;30:1766
  25. Almond PS, Matas A, Gillingham K, et al.  Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55:752
  26. Schäfer AJ, Daniel V, Dreikorn K, et al.  Assessment of plasma neopterin in clinical kidney transplantation. Transplantation. 1986;41:454
  27. Suthanthiran M. Acute rejection of renal allografts (mechanistic insights and therapeutic options). Kidney Int. 1997;51:1289
  28. Pascual M, Vallhonrat H, Cosimi AB, et al.  The clinical usefulness of the renal allograft biopsy in the cyclosporine era (a prospective study). Transplantation. 1999;67:737
  29. Rebhandl W, Felberbauer FX, Resch S, et al.  Value of circulating immune parameters in renal transplantation. Transplant Proc. 1997;29:1881
  30. Pelzl S, Opelz G, Daniel V, et al.  Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation. 2003;75:421
  31. Simon T, Opelz G, Weimer R, et al.  The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant. 2003;17:217
  32. O'Connell PJ, Pacheco-Silva A, Nickerson PW, et al.  Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol. 1993;150:1093
  33. Li B, Hartono C, Ding R, et al.  Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 2001;344:947
  34. Hall BM. Cells mediating allograft rejection. Transplantation. 1991;51:1141
  35. Vasconcellos LM, Schachter AD, Zheng XX, et al.  Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation. 1998;66:562
  36. Simon T, Opelz G, Wiesel M, et al: Serial peripheral blood perforin and granzyme B gene expression measurements for pre-diction of acute rejection in kidney graft recipients. Am J Transplant 3:1121, 2003
  37. Morton AL, Bell EB, Bolton EM, et al.  CD4+ T cell-mediated rejection of major histocompatibility complex class I-disparate grafts (a role for alloantibody). Eur J Immunol. 1993;23:2078
  38. Lederer SR, Kluth-Pepper B, Schneeberger H, et al.  Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 2001;59:334

☆ Supported in part by a grant from the Forschungsschwerpunkt Transplantation Heidelberg.

PII: S0041-1345(03)01230-2

doi: 10.1016/j.transproceed.2003.11.019

Transplantation Proceedings
Volume 36, Issue 1 , Pages 29-34 , January 2004

Article Tools

* Image Usage & Resolution